Assembly Biosciences Inc. [NASDAQ: ASMB] loss -69.37% or -11.03 points to close at $4.87 with a heavy trading volume of 21514707 shares. The company report on November 7, 2020 that Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, announced a grant of stock options to a new employee to purchase 6,520 shares of the Company’s common stock with an exercise price of $14.75 per share, the closing price of Assembly’s common stock on November 2, 2020. The stock options were granted as a material inducement to the new employee to accept the Company’s offer of employment.
The stock options have a ten-year term and vest over four years, with one-fourth vesting on the first anniversary of the date of grant and the remaining three-fourths vesting in approximately equal monthly installments. The stock options are, in all cases, subject to the new employee’s continued service with Assembly through the applicable vesting dates and to acceleration upon the occurrence of certain events as set forth in the award agreement evidencing the stock options. The new employee is not an executive officer.
It opened the trading session at $6.30, the shares rose to $6.35 and dropped to $4.78, the range by which the price of stock traded the whole day. The daily chart for ASMB points out that the company has recorded -76.31% loss over the past six months. However, it is still 52.39% higher than its most recent low trading price.
If we look at the average trading volume of 245.91K shares, ASMB reached to a volume of 21514707 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Assembly Biosciences Inc. [ASMB]:
Jefferies have made an estimate for Assembly Biosciences Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on November 06, 2020. While these analysts kept the previous recommendation, Truist raised their target price to Buy. The new note on the price target was released on October 19, 2020, representing the official price target for Assembly Biosciences Inc. stock. Previously, the target price had yet another raise to $20, while Mizuho analysts kept a Buy rating on ASMB stock.
The Average True Range (ATR) for Assembly Biosciences Inc. is set at 1.62, with the Price to Sales ratio for ASMB stock in the period of the last 12 months amounting to 3.10. The Price to Book ratio for the last quarter was 0.64, with the Price to Cash per share for the same quarter was set at 6.79.
Trading performance analysis for ASMB stock
Assembly Biosciences Inc. [ASMB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -66.96. With this latest performance, ASMB shares dropped by -68.92% in over the last four-week period, additionally sinking by -76.31% over the last 6 months – not to mention a drop of -69.98% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ASMB stock in for the last two-week period is set at 13.88, with the RSI for the last a single of trading hit 10.72, and the three-weeks RSI is set at 17.52 for Assembly Biosciences Inc. [ASMB]. The present Moving Average for the last 50 days of trading for this stock 16.41, while it was recorded at 13.29 for the last single week of trading, and 18.91 for the last 200 days.
Assembly Biosciences Inc. [ASMB]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Assembly Biosciences Inc. [ASMB] shares currently have an operating margin of -630.29. Assembly Biosciences Inc.’s Net Margin is presently recorded at -611.63.
Return on Total Capital for ASMB is now -40.56, given the latest momentum, and Return on Invested Capital for the company is -39.61. Return on Equity for this stock declined to -40.36, with Return on Assets sitting at -31.70. When it comes to the capital structure of this company, Assembly Biosciences Inc. [ASMB] has a Total Debt to Total Equity ratio set at 4.49. Additionally, ASMB Total Debt to Total Capital is recorded at 4.30, with Total Debt to Total Assets ending up at 3.53. Long-Term Debt to Equity for the company is recorded at 3.32, with the Long-Term Debt to Total Capital now at 3.18.
Reflecting on the efficiency of the workforce at the company, Assembly Biosciences Inc. [ASMB] managed to generate an average of -$848,991 per employee. Receivables Turnover for the company is 5.50 with a Total Asset Turnover recorded at a value of 0.05.Assembly Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 13.60 and a Current Ratio set at 13.60.
Assembly Biosciences Inc. [ASMB]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Assembly Biosciences Inc. posted -0.99/share EPS, while the average EPS was predicted by analysts to be reported at -1.01/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 2.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ASMB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Assembly Biosciences Inc. go to 17.00%.
An analysis of insider ownership at Assembly Biosciences Inc. [ASMB]
There are presently around $148 million, or 94.80% of ASMB stock, in the hands of institutional investors. The top three institutional holders of ASMB stocks are: CONSONANCE CAPITAL MANAGEMENT LP with ownership of 3,175,535, which is approximately 0% of the company’s market cap and around 0.60% of the total institutional ownership; ECOR1 CAPITAL, LLC, holding 3,153,797 shares of the stock with an approximate value of $15.36 million in ASMB stocks shares; and BLACKROCK INC., currently with $12.29 million in ASMB stock with ownership of nearly -0.809% of the company’s market capitalization.
Positions in Assembly Biosciences Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 62 institutional holders increased their position in Assembly Biosciences Inc. [NASDAQ:ASMB] by around 2,729,156 shares. Additionally, 36 investors decreased positions by around 1,762,090 shares, while 19 investors held positions by with 25,890,750 shares. The mentioned changes placed institutional holdings at 30,381,996 shares, according to the latest SEC report filing. ASMB stock had 16 new institutional investments in for a total of 659,573 shares, while 9 institutional investors sold positions of 67,272 shares during the same period.